The global cardiac biomarker testing market was valued at USD 4.53 billion in 2023 and is projected to reach USD 10.21 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.47% during the forecast period from 2024 to 2032. This robust growth is propelled by a global surge in cardiovascular disease (CVD) prevalence, increased investment in healthcare infrastructure, and significant advancements in diagnostic technologies.
Growth Drivers Fueling Market Expansion
A primary driver of the cardiac biomarker testing market is the increasing global burden of cardiovascular diseases. According to the World Health Organization, CVDs are responsible for approximately 17.9 million deaths each year, making them the leading cause of mortality worldwide. Early detection through reliable biomarkers has become a cornerstone of cardiac care, prompting demand for more accessible and accurate diagnostic solutions.
Get a Free Sample Report of Cardiac Biomarker Testing Market@ https://www.snsinsider.com/sample-request/5506
Technological innovation continues to redefine the cardiac biomarker testing landscape. High-sensitivity assays capable of detecting minute levels of troponin have enabled clinicians to identify myocardial injury at earlier stages. Portable and point-of-care (POC) devices like Roche’s Cobas and Abbott’s i-STAT systems are now widely implemented in emergency settings, providing rapid and life-saving diagnoses in critical care environments.
Demographic trends further reinforce market growth. With global life expectancy on the rise, age-related cardiac conditions are becoming increasingly common. In the United States, one in four individuals over the age of 65 suffers from heart disease. Cardiac biomarker testing is crucial for this aging population, offering tools for ongoing monitoring and preventive care.
Lifestyle-related risk factors also play a significant role. Sedentary habits, poor nutrition, and tobacco use are contributing to CVD incidence in younger populations. Studies by the American Heart Association have identified these behaviors as major contributors to early-onset heart disease, driving increased consumer demand for proactive diagnostic solutions such as cardiac biomarker tests.
Supportive governmental policies and initiatives are accelerating market penetration. In the U.S., the National Institutes of Health continues to fund cardiovascular research, leading to innovations in biomarker discovery and implementation. Similarly, healthcare reforms and increased diagnostic access in India and China have opened up significant growth avenues in Asia-Pacific.
Market Drivers
Growing Healthcare Investments and Policy Support
Governments worldwide are amplifying investments in diagnostic healthcare, significantly boosting the cardiac biomarker testing market. Policies like the Affordable Care Act in the U.S. have broadened access to preventive diagnostics, incentivizing the integration of cardiac biomarker tests into routine care. These systemic improvements enhance the detection and treatment of cardiovascular conditions, especially in emergency settings.
Rising Prevalence of Comorbidities
The prevalence of diabetes, obesity, and hypertension is rising globally, all of which increase the risk of CVDs. This comorbidity landscape necessitates early diagnostic testing. Cardiac biomarker tests offer non-invasive, accurate results, allowing physicians to intervene early and manage patient risk proactively.
Shift Towards Personalized Medicine and Remote Monitoring
The cardiac biomarker testing market is increasingly benefiting from the healthcare industry’s move toward personalized treatment protocols. Biomarker-guided therapy enables targeted and more effective interventions for individual patients. Moreover, remote monitoring platforms have expanded testing beyond clinical settings, allowing home-based diagnostics and enhancing accessibility for high-risk populations.
Market Restraints
Despite promising growth, the market faces barriers such as the high cost of testing equipment and limited insurance reimbursement. In lower-income regions, these factors restrict access to advanced diagnostic technologies. The lack of clear coverage policies among insurers often places a financial burden on patients, hampering market adoption.
Market Segmentation Overview
By Product Type:
Reagents and kits dominated the market in 2023, comprising 65% of total revenue. Their widespread adoption is linked to consistent performance in high-sensitivity and POC testing. Instruments, on the other hand, are poised for rapid growth due to their automation capabilities and integration with hospital laboratory workflows.
By Biomarker Type:
Troponin biomarkers held a 40% market share in 2023, owing to their unmatched accuracy in detecting acute myocardial infarction. High-sensitivity troponin assays have become the gold standard in many countries. Meanwhile, BNP and NT-proBNP biomarkers are expected to grow fastest due to their vital role in diagnosing heart failure and stratifying cardiovascular risk.
Regional Insights
North America led the cardiac biomarker testing market in 2023, accounting for 40% of global revenue. This dominance stems from widespread CVD prevalence, sophisticated healthcare infrastructure, and proactive diagnostic practices. Favorable insurance policies and rapid adoption of advanced assays like hs-troponin have cemented the region’s market leadership.
Asia-Pacific is emerging as the fastest-growing market. In countries like China and India, cardiovascular diseases cause over 30% of annual deaths. Government-led initiatives like China’s Healthy China 2030 and India’s National Programme for Prevention and Control of Non-Communicable Diseases are instrumental in promoting biomarker-based diagnostics in both urban and rural populations.
Leading Market Players
Roche – Elecsys Troponin T, NT-proBNP
Abbott – ARCHITECT STAT hs-Troponin-I, i-STAT System
Danaher (Beckman Coulter) – Access hs-TnI, BNP
Siemens Healthineers – ADVIA Centaur, Atellica Solution NT-proBNP II
bioMérieux – VIDAS Troponin I Ultra
Thermo Fisher Scientific – B·R·A·H·M·S Cardiac Panel
Bio-Rad Laboratories – Liquichek Cardiac Markers
Tosoh Corporation – AIA-PACK Troponin I
Quidel Corporation – Triage BNP Assay
Recent Developments
In June 2024, Siemens Healthineers launched the NT-proBNPII assay on its Atellica platform, targeting heart failure diagnostics. Similarly, Roche expanded its diagnostics portfolio in 2023 with new cardiac platforms, digital solutions, and strategic R&D investments exceeding CHF 13 million.
Buy a Single-User PDF of Cardiac Biomarker Testing Market Analysis & Outlook Report 2024-5506@ https://www.snsinsider.com/checkout/5506
Conclusion
The cardiac biomarker testing market is on a robust growth trajectory, fueled by escalating cardiovascular disease rates, emerging technologies, and heightened public health awareness. As global healthcare shifts toward preventive care and personalized medicine, the role of cardiac biomarkers in early detection and disease management will only grow stronger, opening new frontiers for innovation and access.
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
